Genomic characterization of baseline and post-progression tumors in IMmotion010, a randomized, phase 3 study of adjuvant (adj) atezolizumab (atezo) vs placebo (pbo) in patients (pts) with high-risk localized renal cell carcinoma (RCC).
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: City Of Hope National Medical Center, City of Hope, Institut Gustave Roussy, Royal Free London NHS Foundation Trust, University College London, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Fox Chase Cancer Center, Genentech, Harvard University, Dana-Farber Cancer Institute, Vanderbilt University Medical Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Roche
OpenAlex ID: W4410822632